Cybin provides corporate update and highlights positive regulatory signals for psychedelic therapeutics

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe canada ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. “it is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program cyb003 in phase 3 development, the path toward approval and eventua.
CYBN Ratings Summary
CYBN Quant Ranking